Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ALT
ALT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALT News
ALT Stock Has Dropped Nearly 50% Over the Last Year, Yet Wall Street Predicts Nearly 500% Growth Potential.
3d ago
stocktwits
AvaíBio Initiates α-Klotho Cell Bank Creation
6d ago
PRnewswire
AvaíBio Initiates Master Cell Bank for α-Klotho Production
6d ago
Newsfilter
Novo Nordisk's High-Dose Wegovy Approved by FDA
Mar 19 2026
CNBC
Truist Initiates Buy Rating on Altimmune, Highlights Pemvidutide's Potential
Mar 18 2026
seekingalpha
Altimmune Reports Q4 2025 Earnings and Phase III Trial Plans
Mar 05 2026
seekingalpha
Altimmune's Financial Status and Trial Progress
Mar 05 2026
stocktwits
Altimmune Announces Late-Stage Trial Plans for Pemvidutide
Mar 05 2026
seekingalpha
Altimmune (ALT) Q4 2025 Earnings Call Transcript
Mar 05 2026
NASDAQ.COM
Altimmune Q4 Earnings Report Analysis
Mar 05 2026
seekingalpha
Altimmune Scheduled to Announce Q4 Earnings on March 5
Mar 04 2026
seekingalpha
Altimmune to Participate in Multiple Investor Conferences
Mar 02 2026
Newsfilter
Analysis of Weight Loss Drug Market Prospects
Feb 26 2026
Fool
Altimmune to Report Q4 2025 Financial Results on March 5
Feb 26 2026
Newsfilter
Eli Lilly's Dominance in Obesity Drug Market Reinforced
Feb 23 2026
CNBC
Altimmune Receives Buy Rating from Analysts Amid Promising Drug Trials
Feb 18 2026
Yahoo Finance
Show More News
